Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors

@article{Fan2016PrognosticVO,
  title={Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors},
  author={Y. Fan and Ke Ma and Chuying Wang and Jing Ning and Yuan Hu and D. Dong and Xuyuan Dong and Q. Geng and E. Li and Yinying Wu},
  journal={OncoTargets and therapy},
  year={2016},
  volume={9},
  pages={6075 - 6082}
}
  • Y. Fan, Ke Ma, +7 authors Yinying Wu
  • Published 2016
  • Biology, Medicine
  • OncoTargets and therapy
Purpose Programmed death 1 (PD-1) receptor and its ligand, programmed death ligand-1 (PD-L1), play critical roles in the immune invasion of various tumors. This study aimed to explore the clinical significance of PD-L1/PD-1 expression in the progression of pulmonary neuroendocrine tumors (PNETs). Methods The expression of PD-L1 and PD-1 in 80 patients diagnosed with PNETs were investigated. Immunohistochemical analysis was performed on 80 formalin-fixed paraffin-embedded tissue specimens from… Expand
Prognostic value of PD-L1 expression in bronchopulmonary neuroendocrine tumours
TLDR
PD-L1 expression is common in BP-NEN, increases with malignancy, and is associated with poor prognosis, therefore, targeting the PD-1/PD- L1 axis could be a promising strategy for treating BP- NEN. Expand
Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas
TLDR
Investigating the expression of PD-L1 on tumor cells and PD-1+, CD8+, and FOXP3+ T cell infiltration by immunohistochemistry in 43 resected G-NEC tissue specimens demonstrated for the first time that high expression ofPD-L 1 in G- NECs is associated with a poor prognosis, while the high expression may be due to the copy number variation of PD -L1 gene or stimulation of TILs. Expand
Expression of PD-1/PD-L1 and P53 in hepatocellular carcinoma: relationship with clinicopathological parameters
TLDR
Blockage of the PD-1 and PD-L1 pathway might be utilized as a methodology to activate immunity in patients with HCC and suggest its role in the immune evasion theory. Expand
PD-1 and PD-L1 expression in pulmonary carcinoid tumors and their association to tumor spread
TLDR
Targeting of the PD-1/PD-L1 pathway with immune checkpoint inhibitors may offer a treatment option for a subset of PC patients after investigating programmed death protein 1 and programmed death ligand 1 expression in PC tumors. Expand
Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors
TLDR
Positive expression of PD-L1 showed no correlation with overall survival or progression-free survival, while higher CD8+ TILs within stroma was proved to be an independent prognostic factor for favorable OS and PFS of PNETs. Expand
Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors
TLDR
The data suggest that PD-1/PD-L1 is expressed in 1 to 8% of GEP-NETs, and that this feature is significantly associated with disease evolution (p < 0.01), and the levels of circulating PD- 1+ PBMCs were associated with progressive disease upon follow-ups. Expand
PD-L1 expression in large cell neuroendocrine carcinoma of the lung.
TLDR
PD-L 1 expression in LCNEC was associated with poorer survival whereas PD-L1 expression in the tumor microenvironment seemed to have a beneficial effect, andTherapeutic approaches have to be evaluated in future. Expand
Intratumoral immune cells expressing PD-1/PD-L1 and their prognostic implications in cancer: a meta-analysis
TLDR
Immune cells expressing PD-1 and PD-L1 within tumors are associated with the prognosis, however, the correlation may vary among different tumor types and by the type of tissue sampling used for the assessment. Expand
PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours
Background The extent of resistance to immune surveillance in patients with well-differentiated (Wd) (grade 1/2) small-intestinal neuroendocrine tumours (Si-NETs) is unknown. Methods PatientsExpand
Prognostic Implications of the Immune Tumor Microenvironment in Patients With Pancreatic and Gastrointestinal Neuroendocrine Tumors
TLDR
Higher intratumoral CD3+ T-cell infiltrate was associated with longer PFS after resection and programmed death-ligand 1 expression tended to be higher among patients with shortened PFS. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 47 REFERENCES
Clinical impact of programmed cell death ligand 1 expression in colorectal cancer.
TLDR
Interestingly, programmed death receptor ligand 1 (PDL-1) and interferon (IFN)-γ gene expression, as detected by quantitative reverse transcriptase polymerase chain reaction (RT-PCR) in fresh frozen CRC specimens were found to be significantly associated with improved survival in MMR-proficient CRC. Expand
Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer
TLDR
The data suggest for the first time that PD-L1 status may be a new predictor of prognosis for patients with pancreatic cancer and provide the rationale for developing a novel therapy of targeting thePD-L/PD-1 pathway against this fatal disease. Expand
Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer
TLDR
The data suggest that PD-L1 and PD- L2 status may be a new predictor of prognosis for patients with esophageal cancer and provide the rationale for developing novel immunotherapy of targeting PD-1/PD-L pathway. Expand
PD-L1 expression in small cell neuroendocrine carcinomas.
TLDR
Besides conventional immunohistochemistry, RNA-seq seems suitable for detection of PD-L1/PD-L2 expression and might prove to be more sensitive and evaluation of the composition of the tumour microenvironment should be included in clinical trials. Expand
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.
TLDR
Clinical trials with mAbs blockading the PD-1/PD-L1 pathway have shown impressive response rates in patients, particularly for melanoma, non-small-cell lung cancer (NSCLC), renal cell carcinoma (RCC), and bladder cancer. Expand
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
TLDR
Overall, the three antibodies provide a significant differential effect in terms of activity according to PD-L1 expression on tumor cells, which seems to be more robust for anti-PD-1 antibody (nivolumab and pembrolizumab), and in the context of advanced melanoma and NSCLC. Expand
PD-1 Is Expressed by Tumor-Infiltrating Immune Cells and Is Associated with Poor Outcome for Patients with Renal Cell Carcinoma
TLDR
Interactions between immune cell PD-1 and B7-H1 may promote cancer progression by contributing to immune dysfunction in patients with RCC, and levels of immune cells expressingPD-1 were increased in Patients with high-risk RCC tumors. Expand
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy
TLDR
Tumor PD-L1 expression reflects an immune-active microenvironment and, while associated other immunosuppressive molecules, including PD-1 andPD-L2, is the single factor most closely correlated with response to anti–PD-1 blockade. Expand
Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer
TLDR
The basic principle of PD-1/PD-L1 pathway and its role in the tumorigenesis and development of NSCLC is discussed and the main problems in the present studies and the research direction in the future will be discussed. Expand
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
TLDR
Antibody-mediated blockade of PD-L1 induced durable tumor regression and prolonged stabilization of disease in patients with advanced cancers, including non-small-cell lung cancer, melanoma, and renal-cell cancer. Expand
...
1
2
3
4
5
...